Target intelligence / Profile preview

T cell receptor beta joining 2-1 (TRBJ2-1)

Target
TRBJ2-1
Molecular classification
Receptor, Antigen receptor component (T cell receptor segment), Other (Immunoglobulin superfamily segment)
01

Overview

T cell receptor beta joining 2-1 (TRBJ2-1) is a gene segment in the beta chain locus of the T cell receptor (TCR), encoding a part of the J (joining) region of the TCR beta subunit in humans[1][4][8]. The TCR is formed through somatic V(D)J recombination, in which one Variable (V), one Diversity (D), and one Joining (J) segment are assembled to create a highly diverse repertoire of antigen-specific receptors on T lymphocytes[3][5]. TRBJ2-1 specifically contributes to the CDR3 (complementarity-determining region 3) loop of the TCR beta chain, a region critical for direct peptide-major histocompatibility complex (MHC) contact during antigen recognition[1][3]. While essential for the adaptive immune system and immune repertoire diversity, TRBJ2-1 itself is a gene segment, not a protein or receptor target of drugs, and is not typically considered a therapeutic target[1][8]. Its primary role is in genetic recombination to ensure T cell diversity and proper immune function[5]. If you are looking for information about the functional T cell receptor complex as a therapeutic target, refer to "T cell receptor (TCR), alpha/beta complex" as a canonical entity.

Other names
TCRBJ2S1TRBJ21TRBJ2-1
02

Biological functions

Adaptive immune responseAntigen recognitionSignal transduction (as part of the T cell receptor complex)
03

Disease associations

Other (Related to immune function and T cell repertoire diversity; not a direct disease target)
04

Safety considerations

Other (Not known as a therapeutic target directly; genomic rearrangements involving TRBJ2-1 may be analyzed in immune monitoring/lymphoid malignancies but not targeted by drugs)

Beyond the preview

Go deeper on T cell receptor beta joining 2-1 (TRBJ2-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 2-1 (TRBJ2-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call